Literature DB >> 28145611

Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.

Brad Tinkle, Marco Castori, Britta Berglund, Helen Cohen, Rodney Grahame, Hanadi Kazkaz, Howard Levy.   

Abstract

The hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the most common hereditary disorder of connective tissue. It has been described largely in those with musculoskeletal complaints including joint hypermobility, joint subluxations/dislocations, as well as skin and soft tissue manifestations. Many patients report activity-related pain and some go on to have daily pain. Two undifferentiated syndromes have been used to describe these manifestations-joint hypermobility syndrome and hEDS. Both are clinical diagnoses in the absence of other causation. Current medical literature further complicates differentiation and describes multiple associated symptoms and disorders. The current EDS nosology combines these two entities into the hypermobile type of EDS. Herein, we review and summarize the literature as a better clinical description of this type of connective tissue disorder.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ehlers-Danlos syndrome hypermobility type; Ehlers-Danlos syndrome type III; joint hypermobility; joint hypermobility syndrome

Mesh:

Year:  2017        PMID: 28145611     DOI: 10.1002/ajmg.c.31538

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  64 in total

1.  Systemic manifestations of Ehlers-Danlos syndrome.

Authors:  Bo Song; Peter Yeh; John Harrell
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-08-26

Review 2.  Urogenital and pelvic complications in the Ehlers-Danlos syndromes and associated hypermobility spectrum disorders: A scoping review.

Authors:  Elizabeth Gilliam; Jodi D Hoffman; Gloria Yeh
Journal:  Clin Genet       Date:  2019-09-01       Impact factor: 4.438

Review 3.  Bone Disease in Patients with Ehlers-Danlos Syndromes.

Authors:  Shuaa Basalom; Frank Rauch
Journal:  Curr Osteoporos Rep       Date:  2020-04       Impact factor: 5.096

4.  Factors affecting quality of life in children and adolescents with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders.

Authors:  Weiyi Mu; Michael Muriello; Julia L Clemens; You Wang; Christy H Smith; Phuong T Tran; Peter C Rowe; Clair A Francomano; Antonie D Kline; Joann Bodurtha
Journal:  Am J Med Genet A       Date:  2019-01-31       Impact factor: 2.802

5.  Use of Cluster Analysis to Delineate Symptom Profiles in an Ehlers-Danlos Syndrome Patient Population.

Authors:  Jane R Schubart; Eric Schaefer; Alan J Hakim; Clair A Francomano; Rebecca Bascom
Journal:  J Pain Symptom Manage       Date:  2019-05-31       Impact factor: 3.612

Review 6.  The Ehlers-Danlos syndromes.

Authors:  Fransiska Malfait; Marco Castori; Clair A Francomano; Cecilia Giunta; Tomoki Kosho; Peter H Byers
Journal:  Nat Rev Dis Primers       Date:  2020-07-30       Impact factor: 52.329

Review 7.  Ehlers-Danlos syndrome: what the radiologist needs to know.

Authors:  Michael P George; Natasha E Shur; Jeannette M Peréz-Rosselló
Journal:  Pediatr Radiol       Date:  2021-05-17

Review 8.  Genetic causes of fractures and subdural hematomas: fact versus fiction.

Authors:  Natasha E Shur; Maxwell L Summerlin; Bruce J McIntosh; Eglal Shalaby-Rana; Tanya S Hinds
Journal:  Pediatr Radiol       Date:  2021-05-17

Review 9.  Vascular Genetics: Presentations, Testing, and Prognostics.

Authors:  Aaron W Aday; Sarah E Kreykes; Christina L Fanola
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-11-13

10.  Low- and high-anxious hypermobile Ehlers-Danlos syndrome patients: comparison of psychosocial and health variables.

Authors:  Carolina Baeza-Velasco; Caroline Bourdon; Lucile Montalescot; Cécile de Cazotte; Guillem Pailhez; Antonio Bulbena; Claude Hamonet
Journal:  Rheumatol Int       Date:  2018-03-01       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.